title: Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium?
abstract: The aim of this study was to determine whether or not the use of medical pre-treatment of the endometrium improves the outcome of transcervical resection of the endometrium with regards to long-term operative outcome, histological findings and patient satisfaction. A prospective randomized trial comparing three endometrial pre-treatment agents (danazol, medroxyprogesterone acetate or nafarelin) with no pre-treatment was conducted. The main outcome measures were: (i) thickness of the endometrium and myometrium resected; (ii) histological stage of the endometrium at the time of operation; (iii) the presence or absence of menses and (iv) patient satisfaction 1 year post-operatively. Of the three pre-treatments studied, danazol produced a lower median endometrial thickness than the control, showed the greatest ability to induce atrophy of the endometrial glands and stroma (not statistically significant) and produced the highest rate of amenorrhoea (not different to the control). Danazol and nafarelin produced significantly lower median endometrial thickness than no pre-treatment. There were, however, no significant differences in the rates of amenorrhoea in any of the pre-treatment groups compared with that in the control group. No improvement in clinical outcome or patient satisfaction is conferred by the use of medical pre-treatments if transcervical resection of the endometrium is performed in the proliferative phase of the menstrual cycle.
authors.affiliation: Department of Obstetrics and Gynaecology, and Department of Cellular Pathology, John Radcliffe Hospital, Headington, Oxford, UK. vrai77@hotmail.com
authors.forename: V S
authors.initials: VS
authors.lastname: Rai
authors.forename: M D
authors.initials: MD
authors.lastname: Gillmer
authors.forename: W
authors.initials: W
authors.lastname: Gray
mesh_terms: D000568:Amenorrhea / Q000473:pathology; D003613:Danazol / Q000627:therapeutic use; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008595:Menorrhagia / Q000473:pathology / Q000601:surgery; D017274:Nafarelin / Q000627:therapeutic use; D017060:Patient Satisfaction; D011292:Premedication; D011446:Prospective Studies; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000473:pathology / Q000601:surgery
chemical_list: D004965:Estrogen Antagonists; D006728:Hormones; D017274:Nafarelin; D017258:Medroxyprogesterone Acetate; D003613:Danazol